Anteris Technologies Global Corp. (ASX:AVR)
7.55
-0.33 (-4.19%)
Nov 20, 2026, 2:12 PM AEDT
ASX:AVR Revenue
Anteris Technologies Global had revenue of $519.00K USD in the quarter ending September 30, 2026, with 20.98% growth. This brings the company's total for the last twelve months to $2.33M, up 9.02% year-over-year. In the year 2025, Anteris Technologies Global had annual revenue of $1.91M, down -29.23%.
Revenue (ttm)
$2.33M
Revenue Growth
+9.02%
P/S Ratio
218.36
Revenue / Employee
$13.40K
Employees
174
Market Cap
732.27M AUD
Revenue by Geography
- United States 1.61M 84.1%
- Germany 272.00K 14.2%
- Australia 33.00K 1.7%
Fiscal year ended Dec 31, 2025 See the full ASX:AVR breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.91M | -790.00K | -29.23% |
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cochlear | 2.35B |
| PolyNovo | 149.85M |
| Saluda Medical | 130.35M |
| SomnoMed | 114.53M |
| Aroa Biosurgery | 86.47M |
| Cyclopharm | 34.42M |
| Lumos Diagnostics Holdings | 19.07M |
| EBR Systems | 12.11M |
Anteris Technologies Global News
- 4 minutes ago - Anteris' DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli - GlobeNewsWire
- 5 days ago - Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - GlobeNewsWire
- 8 days ago - Anteris Technologies price target lowered to $9 from $10 at Barclays - TheFly
- 11 days ago - Anteris Technologies Announces Results for the Third Quarter of 2026 - GlobeNewsWire
- 20 days ago - Anteris Technologies announces 30-day outcomes for medium-size DurAVR THV - TheFly
- 20 days ago - Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026 - GlobeNewsWire
- 26 days ago - Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026 - GlobeNewsWire
- 4 weeks ago - Anteris Technologies gets full clearance from German BfArM for DurAVR THV - TheFly